Video
Dr. Lowentritt on study comparing PSA response of apalutamide and enzalutamide in mCSPC
Author(s):
“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.
In this video, Benjamin Lowentritt, MD, FACS, discusses the background and findings of the study, “Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.
Related Videos
Related Content
